The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy
Abstract
BACKGROUND: In patients with venous thromboembolism (VTE), identifying clinical risk factors for recurrence during the initial 3 months of anticoagulant therapy and knowledge of the time course of recurrence may help clinicians decide about the frequency of clinical surveillance and the appropriateness of outpatient treatment. METHODS: Analysis of a randomized controlled trial database involving 1021 patients with VTE (750 with deep vein thrombosis [DVT] and 271 with pulmonary embolism [PE]) who were followed up for 3 months after the start of anticoagulant therapy. All patients received initial treatment with unfractionated heparin or a low-molecular-weight heparin (reviparin) and a coumarin derivative starting the first or second day of treatment, with a target international normalized ratio of 2.0 to 3.0. RESULTS: Four independent clinical risk factors for recurrent VTE were identified: (1) cancer (odds ratio [OR], 2.72; 95% confidence interval [CI], 1. 39-5.32), (2) chronic cardiovascular disease (OR, 2.27; 95% CI, 1. 08-4.97), (3) chronic respiratory disease (OR, 1.91; 95% CI, 0.85-4. 26), and (4) other clinically significant medical disease (OR, 1.79; 95% CI, 1.00-3.21). Older age was associated with a decreased risk for recurrent VTE (OR, 0.76; 95% CI, 0.64-0.92). Previous VTE, sex, and idiopathic VTE were not risk factors for recurrence. In patients with DVT or PE, there was no significant difference in the rates of recurrent nonfatal VTE (4.8% vs 4.1%; P =.62), major bleeding (2.9% vs 2.2%; P =.53), and non-VTE death (6.4% vs 7.8%; P =.45), but recurrent fatal PE was more frequent in patients with PE than DVT (2. 2% vs 0%; P<.01). There was a clustering of recurrent VTE episodes during the initial 2 to 3 weeks after the start of treatment. CONCLUSIONS: During the initial 3 months of anticoagulant therapy, recurrent VTE is more likely to occur in patients with cancer, chronic cardiovascular disease, chronic respiratory disease, or other clinically significant medical disease. Patients with PE are as likely to develop recurrent VTE as those with DVT; however, recurrence is more likely to be fatal in patients who initially present with PE. Arch Intern Med. 2000;160:3431-3436.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Self-citationHemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citationSchulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
HULL, R. D., HIRSH, J., CARTER, C. J., JAY, R. M., DODD, P. E., OCKELFORD, P. A., COATES, G., GILL, G. J., TURPIE, A. G., DOYLE, D. J., et al. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-891 · Cited by 645
Risk of Fatal Pulmonary Embolism in Patients With Treated Venous Thromboembolism
Douketis, J. D. (1998) · JAMA · doi:10.1001/jama.279.6.458 · Cited by 617
Self-citationThe Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S.-G., Nordlander, S., Lärfars, G., Leijd, B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702063360601 · Cited by 604
NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS
LAGERSTEDT, C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90459-3 · Cited by 569
Schulman, S., Svenungsson, E., & Granqvist, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00060-6 · Cited by 497
De Stefano, V., Martinelli, I., Mannucci, P. M., Paciaroni, K., Chiusolo, P., Casorelli, I., Rossi, E., & Leone, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411104 · Cited by 482
Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism
Kuijer, P. M. M., Hutten, B. A., Prins, M. H., & Büller, H. R. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.457 · Cited by 416
Self-citationMortality in Patients Treated for Pulmonary Embolism
Alpert, J. S. (1976) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1976.03270140029017 · Cited by 374
Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P., et al. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649783 · Cited by 353
Self-citationOptimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
Research Committee of the British Thoracic Society (1992) · The Lancet · doi:10.1016/0140-6736(92)93285-u · Cited by 320
Gallus, A., Tillett, J., Jackaman, J., Mills, W., & Wycherley, A. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91431-5 · Cited by 305
A simple ultrasound approach for detection of recurrent proximal-vein thrombosis.
Prandoni, P., Cogo, A., Bernardi, E., Villalta, S., Polistena, P., Simioni, P., Noventa, F., Benedetti, L., & Girolami, A. (1993) · Circulation · doi:10.1161/01.cir.88.4.1730 · Cited by 303
Wells, P. S., Kovacs, M. J., Bormanis, J., Forgie, M. A., Goudie, D., Morrow, B., & Kovacs, J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1809 · Cited by 281
Gitter, M. J., Jaeger, T. M., Petterson, T. M., Gersh, B. J., & Silverstein, M. D. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.725 · Cited by 276
A standard heparin nomogram for the management of heparin therapy
Cruickshank, M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.2.333 · Cited by 266
Landefeld, C. S., Cook, E. F., Flatley, M., Weisberg, M., & Goldman, L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90004-0 · Cited by 264
Long-term Outcomes of Deep-Vein Thrombosis
Beyth, R. J. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.10.1031 · Cited by 231
Assessment of Outpatient Treatment of Deep-Vein Thrombosis With Low-Molecular-Weight Heparin
Harrison, L., McGinnis, J., Crowther, M., Ginsberg, J., & Hirsh, J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.18.2001 · Cited by 202
Self-citationExtrinsic-pathway activation in cancer with high factor Vlla and tissue factor
Kakkar, A. K., DeRuvo, N., Chinswangwatanakul, V., Tebbutt, S., & Williamson, R. C. N. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91690-3 · Cited by 199
Major bleeding after hospitalization for deep-venous thrombosis
White, R. H., Beyth, R. J., Zhou, H., & Romano, P. S. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00267-3 · Cited by 198
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Weg, J. G., Morris, T. A., Samama, M., & Tapson, V. (1998) · Chest · doi:10.1378/chest.114.5_supplement.561s · Cited by 175
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
The prethrombotic state in cancer.
Luzzatto, G., & Schafer, A. I. (1990) · PubMed · Cited by 163
Heijboer, H., Jongbloets, L. M. M., Buller, H. R., Lensing, A. W. A., & ten Cate, J. W. (1992) · Acta Radiologica · doi:10.1080/02841859209173182 · Cited by 93
White, R. H. R., Zhou, H., & Romano, P. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1005 · Cited by 93
Landefeld, C. S., McGuire, E. J., & Rosenblatt, M. W. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90174-c · Cited by 86
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
Wester, J. P., de Valk, H. W., Nieuwenhuis, H. K., Brouwer, C. B., van der Graaf, Y., Meuwissen, O. J., Hart, H. C., Sixma, J. J., & Banga, J. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650643 · Cited by 53
Heijboer, H., Jongbloets, L. M. M., Buller, H. R., Lensing, A. W. A., & ten Cate, J. W. (1992) · Acta Radiologica · doi:10.1177/028418519203300403 · Cited by 47
Outpatient treatment of deep vein thrombosis: translating clinical trials into practice
Dunn, A. S., & Coller, B. S. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00129-1 · Cited by 38
Home treatment of deep vein thrombosis: a two-years experience of a single institution.
Grau, E., Real, E., Pastor, E., Viciano, V., & Aguiló, J. (1998) · PubMed · Cited by 36
(1996) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(96)80013-7 · Cited by 22
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Self-citationPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Self-citation
Metadata
- Authors
- Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-12-11
- Volume
- 160
- Issue
- 22
- Pages
- 3431
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2158662386
- Cited by
- 269
- References
- 40
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.